mhurhangee/ep-ind-claims huggingface dataset:
An isolated antibody, or antigen-binding fragment thereof, specific for folate receptor alpha (FRα) comprising a. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 10, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 11, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 12, a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 14, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 15, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 16; or b. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 18, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 19, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 20, a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 22, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 23, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 24. a. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 10, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 11, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 12, a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 14, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 15, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 16; or b. a light chain CDR1 having the amino acid sequence of SEQ ID NO: 18, a light chain CDR2 having the amino acid sequence of SEQ ID NO: 19, a light chain CDR3 having the amino acid sequence of SEQ ID NO: 20, a heavy chain CDR1 having the amino acid sequence of SEQ ID NO: 22, a heavy chain CDR2 having the amino acid sequence of SEQ ID NO: 23, and a heavy chain CDR3 having the amino acid sequence of SEQ ID NO: 24.
A method of updating Electronic Control Units (ECUs) of vehicles using updates received via Vehicle to Vehicle, V2V, communication channels and verified by a vehicles consensus, comprising: using at least one processor of a vehicle executing a code for: receiving from at least one nearby vehicle, via at least one V2V communication channel, at least one of a plurality of update packages distributed for updating a plurality of ECUs deployed in a plurality of vehicles, the at least one nearby vehicle is within a reception area of the at least one V2V communication channel; analyzing an identifier extracted from the at least one update package; determining, based on the analysis, whether the at least one update package is directed to at least one ECU of the vehicle; communicating, in case of positive determination, via the at least one V2V communication channel with at least a subset of the plurality of vehicles, wherein each of the plurality of vehicles maintains a local log associating each of the plurality of update packages with a respective verification code; validating the verification code extracted from the at least one update package according to a consensus of the subset of vehicles; and initiating update, in case of successful validation, of the at least one ECU using the at least one update package; wherein a predefined no transmission period is applied between subsequent transmissions of the update package during which the update package is not transmitted, and a predefined no reception period is applied following the reception of the update package during which reception of update packages is prohibited. receiving from at least one nearby vehicle, via at least one V2V communication channel, at least one of a plurality of update packages distributed for updating a plurality of ECUs deployed in a plurality of vehicles, the at least one nearby vehicle is within a reception area of the at least one V2V communication channel; analyzing an identifier extracted from the at least one update package; determining, based on the analysis, whether the at least one update package is directed to at least one ECU of the vehicle; communicating, in case of positive determination, via the at least one V2V communication channel with at least a subset of the plurality of vehicles, wherein each of the plurality of vehicles maintains a local log associating each of the plurality of update packages with a respective verification code; validating the verification code extracted from the at least one update package according to a consensus of the subset of vehicles; and initiating update, in case of successful validation, of the at least one ECU using the at least one update package; wherein a predefined no transmission period is applied between subsequent transmissions of the update package during which the update package is not transmitted, and a predefined no reception period is applied following the reception of the update package during which reception of update packages is prohibited.
Biologically degradable composite material for bone reconstruction or replacement having an open-porous base structure, characterised in that the composite material contains at least an inorganic component (a); an inorganic component (b); and at least one organic component (c); wherein the inorganic component (a) is a granular material containing biologically active, polygonal, rounded particles which consist of calcium phosphate and/or sodium-containing and/or potassium-containing and/or calcium-containing and/or silicate-containing acidic and/or neutral and/or alkaline bioglass, glass ceramics or mixtures thereof, and each granule has an intragranular porosity of 30-40 % by volume, based on the volume of the granule; the inorganic component (b) is a granular material containing biologically active, polygonal, rounded particles which consist of calcium phosphate and/or sodium-containing and/or potassium-containing and/or calcium-containing and/or silicate-containing acidic and/or neutral and/or alkaline bioglass, glass ceramics or mixtures thereof, and each granule has an intragranular porosity of 60-70 % by volume, based on the volume of the granule; and the densities of the inorganic component (a) and the inorganic component (b) are different; and the at least one organic component (c) is selected from gelatin, collagen, glycosaminoglycan, hyaluronan, sodium hyaluronate, calcium hyaluronate, methyl cellulose, ethyl cellulose, propyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, starch, dextran, hydroxyethyl starch, alginate, polyethylene glycol, albumin, chitosan, organically processed or demineralised allogenic or xenogenic bone, synthetic polypeptide, parathormone, osteogenic protein, or a combination thereof.
A fault-point-locating device that is configured to locate a fault point in a gas-insulated switchgear including a first tank having a breaker for a first phase accommodated therein, a second tank having a breaker for a second phase accommodated therein, and a third tank having a breaker for a third phase accommodated therein, the fault-point-locating device comprising: a measurement unit configured to measure a waveform of a current flowing between the first tank and a grounding electrode, a waveform of a current flowing between the second tank and the grounding electrode, and a waveform of a current flowing between the third tank and the grounding electrode, the first tank, the second tank, and the third tank being connected to the grounding electrode; a location processing unit configured to perform a process of locating the fault point in the first tank, the second tank, and the third tank on a basis of a measurement result of a waveform of each of the currents, wherein the location processing unit is configured to locate the fault point on a basis of one of the currents being out of phase with each of the other two of the currents; and a determination unit configured to determine whether a pressure increase has occurred in each of the first tank, the second tank, and the third tank, characterized in that the location processing unit is configured to perform the process of locating the fault point on a basis of a determination result of whether the pressure increase has occurred, and a measurement result of a waveform of each of the currents. a measurement unit configured to measure a waveform of a current flowing between the first tank and a grounding electrode, a waveform of a current flowing between the second tank and the grounding electrode, and a waveform of a current flowing between the third tank and the grounding electrode, the first tank, the second tank, and the third tank being connected to the grounding electrode; a location processing unit configured to perform a process of locating the fault point in the first tank, the second tank, and the third tank on a basis of a measurement result of a waveform of each of the currents, wherein the location processing unit is configured to locate the fault point on a basis of one of the currents being out of phase with each of the other two of the currents; and a determination unit configured to determine whether a pressure increase has occurred in each of the first tank, the second tank, and the third tank, characterized in that the location processing unit is configured to perform the process of locating the fault point on a basis of a determination result of whether the pressure increase has occurred, and a measurement result of a waveform of each of the currents.
An isolated nucleic-acid fragment comprising: a nucleotide sequence encoding a plant acyl-ACP thioesterase wherein said thioesterase has substrate specificity for a C16 acyl-ACP and catalyzes the hydrolysis of palmitoyl, stearoyl and oleoyl-ACP thioesters and demonstrates more than 90% overall identity to the DNA sequences encoding the mature functional protein encoded by nucleotides 273 to 1226 of SEQ ID NO:2 or nucleotides 482 to 1438 of SEQ ID NO:31, or a part of the sequence of nucleotides 1 to 1483 of SEQ ID NO:2 or nucleotides 1 to 1674 of SEQ ID NO:31 wherein said part is useful in co-suppression of expression of endogenous acyl-ACP thioesterase. a nucleotide sequence encoding a plant acyl-ACP thioesterase wherein said thioesterase has substrate specificity for a C16 acyl-ACP and catalyzes the hydrolysis of palmitoyl, stearoyl and oleoyl-ACP thioesters and demonstrates more than 90% overall identity to the DNA sequences encoding the mature functional protein encoded by nucleotides 273 to 1226 of SEQ ID NO:2 or nucleotides 482 to 1438 of SEQ ID NO:31, or a part of the sequence of nucleotides 1 to 1483 of SEQ ID NO:2 or nucleotides 1 to 1674 of SEQ ID NO:31 wherein said part is useful in co-suppression of expression of endogenous acyl-ACP thioesterase.
A membrane strip biosensor using a lateral flow, the biosensor comprising: a reaction membrane; an asymmetric membrane positioned on the reaction membrane; and a reactant storing part positioned on the asymmetric membrane and having been pre-treated with a reactant, wherein the asymmetric membrane has an asymmetric porous structure such that pores in a part of the asymmetric membrane proximate to the reactant storing part are larger in size than pores in a part of the asymmetric membrane that is proximate to the reaction membrane. a reaction membrane; an asymmetric membrane positioned on the reaction membrane; and a reactant storing part positioned on the asymmetric membrane and having been pre-treated with a reactant, wherein the asymmetric membrane has an asymmetric porous structure such that pores in a part of the asymmetric membrane proximate to the reactant storing part are larger in size than pores in a part of the asymmetric membrane that is proximate to the reaction membrane.
A population of isolated adherent amnion-chorion stem cells, wherein said amnion-chorion stem cells express the gene ST6GALNAC5 at a level at least two-fold higher than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs) that have been grown under equivalent conditions and have undergone the same number of passages in culture as said amnion-chorion stem cells, wherein said amnion-chorion stem cells are CD10 +, CD34 -, CD105 +, and CD200 +.
Method for initializing a dosing unit of an ambulatory infusion system, the method including carrying out a first priming routine, the first priming routine including: - providing the dosing unit with a dosing chamber of the dosing unit having a minimal dosing chamber volume, a draining valve of the dosing unit being closed and a filling valve of the dosing unit being open; - measuring an initial reservoir fluid pressure p 2 and computing, based on the initial reservoir fluid pressure p 2, a first priming volume v 1, with a liquid drug reservoir being fluidic coupled with the dosing chamber via a reservoir coupling conduit and the opened filling valve; - increasing the dosing chamber volume by the first priming volume v 1, with the first priming volume v 1 being computed such that the reservoir coupling conduit is filled with liquid drug substantially completely at the end of the dosing chamber volume increasing; - closing the filling valve and opening the draining valve; - emptying the dosing unit by decreasing the dosing chamber volume to the minimal dosing chamber volume. - providing the dosing unit with a dosing chamber of the dosing unit having a minimal dosing chamber volume, a draining valve of the dosing unit being closed and a filling valve of the dosing unit being open; - measuring an initial reservoir fluid pressure p 2 and computing, based on the initial reservoir fluid pressure p 2, a first priming volume v 1, with a liquid drug reservoir being fluidic coupled with the dosing chamber via a reservoir coupling conduit and the opened filling valve; - increasing the dosing chamber volume by the first priming volume v 1, with the first priming volume v 1 being computed such that the reservoir coupling conduit is filled with liquid drug substantially completely at the end of the dosing chamber volume increasing; - closing the filling valve and opening the draining valve; - emptying the dosing unit by decreasing the dosing chamber volume to the minimal dosing chamber volume.
An adaptive modulation control method, comprising: controlling, in response to a real terminal being in a first signal transmission mode, a modulation and coding scheme, MCS, of the real terminal according to a first adaptive module control, AMC, policy; and enabling, after a change of the signal transmission mode of the real terminal, a second AMC policy conforming to a second signal transmission mode after the change to control the MCS of the real terminal; wherein an outer-loop policy of the first AMC policy is determined on the basis of a first target block error ratio, BLER, while an outer-loop policy of the second AMC policy is determined on the basis of a second target BLER; characterised in that: the real terminal is a physical terminal, and the change of the signal transmission mode of the real terminal comprises at least one of the following: the signal transmission mode of the real terminal is switched between a non-beamforming mode and a beamforming mode; the signal transmission mode of the real terminal is switched between a non-space division multiplexing access, SDMA, mode and an SDMA mode; and the real terminal exits from one space division group and joins another space division group. controlling, in response to a real terminal being in a first signal transmission mode, a modulation and coding scheme, MCS, of the real terminal according to a first adaptive module control, AMC, policy; and enabling, after a change of the signal transmission mode of the real terminal, a second AMC policy conforming to a second signal transmission mode after the change to control the MCS of the real terminal; wherein an outer-loop policy of the first AMC policy is determined on the basis of a first target block error ratio, BLER, while an outer-loop policy of the second AMC policy is determined on the basis of a second target BLER; characterised in that: the real terminal is a physical terminal, and the change of the signal transmission mode of the real terminal comprises at least one of the following: the signal transmission mode of the real terminal is switched between a non-beamforming mode and a beamforming mode; the signal transmission mode of the real terminal is switched between a non-space division multiplexing access, SDMA, mode and an SDMA mode; and the real terminal exits from one space division group and joins another space division group. the signal transmission mode of the real terminal is switched between a non-beamforming mode and a beamforming mode; the signal transmission mode of the real terminal is switched between a non-space division multiplexing access, SDMA, mode and an SDMA mode; and the real terminal exits from one space division group and joins another space division group.
A virtualized network function scale-out method, comprising: determining, by a management and orchestration, MANO, when a delay of a response to a request of a user accessing a first virtualized network function, VNF, exceeds a tolerance time of the user and a second VNF cannot satisfy a requirement of a user accessing the second VNF, that the first VNF and the second VNF satisfy a joint scale-out condition, wherein the second VNF is a downstream VNF of the first VNF, the joint scale-out condition indicates the first VNF and the second VNF satisfy scale-out condition; and scaling out, by the MANO, the first VNF and the second VNF, wherein a process of scaling out the first VNF and a process of scaling out the second VNF completely overlap or partially overlap. determining, by a management and orchestration, MANO, when a delay of a response to a request of a user accessing a first virtualized network function, VNF, exceeds a tolerance time of the user and a second VNF cannot satisfy a requirement of a user accessing the second VNF, that the first VNF and the second VNF satisfy a joint scale-out condition, wherein the second VNF is a downstream VNF of the first VNF, the joint scale-out condition indicates the first VNF and the second VNF satisfy scale-out condition; and scaling out, by the MANO, the first VNF and the second VNF, wherein a process of scaling out the first VNF and a process of scaling out the second VNF completely overlap or partially overlap.
A compound having the formula: wherein R 1, R 2, R 3, R 4, R A, R B, and R C, are independently selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof; wherein R A, R B, and R C may represent mono, di, tri, or tetra substitutions; wherein at least one of R 1, R 2, R 3, and R 4 is not hydrogen or deuterium; wherein two adjacent substituents R 1, R 2, R 3 and R 4 are joined to form a fused ring; wherein X is selected from the group consisting of O, S, and Se; and wherein m is 1 or 2. wherein R 1, R 2, R 3, R 4, R A, R B, and R C, are independently selected from the group consisting of hydrogen, deuterium, alkyl, cycloalkyl, aryl, heteroaryl, and combinations thereof; wherein R A, R B, and R C may represent mono, di, tri, or tetra substitutions; wherein at least one of R 1, R 2, R 3, and R 4 is not hydrogen or deuterium; wherein two adjacent substituents R 1, R 2, R 3 and R 4 are joined to form a fused ring; wherein X is selected from the group consisting of O, S, and Se; and wherein m is 1 or 2.
Treatment vessel screen arrangement for withdrawing treatment liquors in vertically oriented and generally cylindrical treatment vessels in continuous treatment vessel systems, said treatment vessel comprising an outer cylindrical pressure vessel wall with a withdrawal compartment between the pressure wall and a screen with withdrawal slots facing a descending column of cellulosic material in the treatment vessel, and a mounting frame (20a, 20b, 21a, 21b) for said screen attached to the pressure wall, characterized in that the screen has an upper and lower flat vertical tongue (SC UE, SC LE respectively), where first the upper flat tongue (SC UE) can be slided into an upper recess (U RE) in an upper edge of the frame while holding the screen slightly inclined versus the vertical and thereafter while first tilting the screen to a vertical position sliding the lower flat vertical tongue (SC LE) into a lower recess (L RE) in a lower edge of the frame into a seating position where the screen in the seating position is form locked radially into position by both the upper and lower recess, wherein the vertical dimension (V SC) of the screen has a length exceeding the vertical dimension between an upper and a lower horizontal frame member of a mounting frame, and wherein an upper edge (SC UE) of the screen is formed like a vertically directed first flat tongue insert able in a vertically oriented upper recess (U RE) located below and radially outside of an interior treatment vessel plate (D PL) forming part of the mounting frame above the screen, and where a lower edge (SC LE) of the screen includes a second flat tongue insert able in a vertically oriented lower recess (L RE) located in the mounting frame below the screen, whereas the vertical distance (V B) between the bottoms of the upper and lower recess exceed the distance between the vertical distance (V SC) between the upper end of the upper tongue and the lower end of the lower tongue.
Packaging unit for a plurality of individual products assembled to form a group, wherein the individual products have a shape in which at least one side is corrugated, inclined, curved or otherwise uneven and/or the individual products have an anisotropic structure or an anisotropic construction, the packaging unit comprising a plastic bag which accommodates the group of individual products and a stiffening element which is provided in the plastic bag or around the plastic bag, wherein the stiffening element is manufactured from a material having a higher stiffness than the plastic bag, wherein the stiffening element is designed as exactly one banderole which partially surrounds the group of individual products, wherein the banderole is unclosed and has two free ends, wherein the banderole extends as a whole over three adjacent sides of the group of individual products, wherein the banderole runs along a top side serving for a removal of the products during regular use or a bottom side, opposite said top side, of the group of individual products, and also along sides of the group that are arranged on the left and right during a removal during regular use, or the banderole runs along a top side serving for a removal of the products during regular use or a bottom side, opposite said top side, of the group of individual products, and also along a front side provided for a sales presentation and a rear side, opposite said front side, of the group of individual products, wherein at least one portion of the banderole that runs along the top side or the bottom side of the group of individual products has a width which corresponds to a width of an associated top side or bottom side of the group of individual products, characterized in that at least one wing which extends at least partially over an adjacent side of the group of individual products is provided on the portion, and the free ends of the banderole project over the bottom side or top side, opposite the portion, of the group of individual products or are bent over to the bottom side or top side, opposite the portion, of the group of individual products.
A process for producing a pyridine compound from a crude pyridine compound comprising a reaction step of allowing the crude pyridine compound to react with an aluminum hydride compound and a distillation step of distilling the product obtained from the reacting step; wherein impurities contained in the crude pyridine comprise a diazine compound.